A Phase 2 interventional study of voriconazole (Vfend) in Candidiasis and Candidemia, sponsored by Pfizer. Completed at 14 sites in United States. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2011-01-28.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Candidemia by Pfizer — none open to participants now, none under way, none of them phase 3. Candidemia · Pfizer.
Among the 15 studies in Candidemia by Pfizer, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is one of 6 that started in 2008, is one of 2 in phase 2, and was the 7th registered.
73 studies on the registry are indexed under Candidemia; 5 are open to participants now.
Browse Candidemia studies →None of the 15 studies in Candidemia by Pfizer is open now. The open studies under Candidemia, anywhere →
Of the 2 Candidemia studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 2 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 63 across 44 interventional studies indexed under Candidemia.
Median enrollment 49 across the 12 interventional studies, 244 across the 3 observational. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Candidemia by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down. Since we know the dose in adults, and we think we know the matching doses in the young patients ages 2 to 12 years old, we will compare the amount of drug that goes into the system with what we know works in adults. We give the drug by a needle directly into the blood, then few days later we stop that and give the drug by mouth. Meanwhile, we draw a little bit of blood at certain times to measure the drug in it.
73 studies on the registry are indexed under Candidemia; 5 are open to participants now.
This study's enrollment of 40 is below the median of 63 across 44 interventional studies indexed under Candidemia.
Browse Candidemia studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Candidemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Candidiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunocompromised children aged 2 to \<12 years who are at high risk for systemic fungal infection.
Drug: voriconazole (Vfend)
Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h Notes: 1. If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose. 2. Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30. (IV = Intravenous; POS = Powder for oral suspension)
Also known as: UK-109,496; Vfend; voriconazole
Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time frame: Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration
Time frame: Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Time to Reach Cmax (Tmax) Following IV Administration
Time frame: Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
AUC12,ss Following Oral Administration
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time frame: Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose
Cmax,ss Following Oral Administration
Time frame: Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose
Tmax Following Oral Administration
Time frame: Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose
AUC12 Following IV Loading Dose
AUC12 = Area under the plasma concentration-time profile from time zero (predose) to twelve hours. AUC12 was obtained by the Linear/Log trapezoidal method.
Time frame: Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Cmax Following an IV Loading Dose
Time frame: Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Tmax Following an IV Loading Dose
Time frame: Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Trough Concentrations (Cmin)
Time frame: Day 7 (up to Day 20 or more) for IV; Day 7 (or later) for oral at predose
AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time frame: Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
Time frame: Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
Zero Tmax refers to the highest concentration observed for one participant at predose. The profile of the metabolite is relatively flat, which could result in slight variation in sample collection or assay process.
Time frame: Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time frame: Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose
Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Time frame: Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose
Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Time frame: Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose
| Milestone | All Participants |
|---|---|
| Started | 40 |
| Completed | 34 |
| Not completed | 6 |
| Withdrew: Adverse event | 6 |
| Milestone | All Participants |
|---|---|
| Started | 34 |
| Completed | 31 |
| Not completed | 3 |
| Withdrew: Other | 3 |
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Voriconazole IV |
|---|---|
| Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration | 21.42 ± 35.05 |
| μg/mL | Voriconazole IV |
|---|---|
| Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration | 4.26 ± 3.73 |
| hours | Voriconazole IV |
|---|---|
| Time to Reach Cmax (Tmax) Following IV Administration | 2.30 (1.00 to 4.07) |
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Voriconazole Oral |
|---|---|
| AUC12,ss Following Oral Administration | 18.64 ± 50.63 |
| μg/mL | Voriconazole Oral |
|---|---|
| Cmax,ss Following Oral Administration | 3.62 ± 4.66 |
| hours | Voriconazole Oral |
|---|---|
| Tmax Following Oral Administration | 1.07 (0.73 to 8.03) |
AUC12 = Area under the plasma concentration-time profile from time zero (predose) to twelve hours. AUC12 was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Voriconazole IV |
|---|---|
| AUC12 Following IV Loading Dose | 7.85 ± 6.71 |
| μg/mL | Voriconazole IV |
|---|---|
| Cmax Following an IV Loading Dose | 2.15 ± 1.10 |
| hours | Voriconazole IV |
|---|---|
| Tmax Following an IV Loading Dose | 2.30 (1.72 to 4.08) |
| μg/mL | All Treatments |
|---|---|
| IV Day 7 (up to Day 20) (n=36) | 0.61 ± 2.56 |
| Oral Day 7 (up to Day 30) (n=32) | 0.52 ± 3.32 |
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Voriconazole IV |
|---|---|
| Day 1 | 20.98 ± 8.05 |
| Day 7 (up to Day 20) | 41.95 ± 14.30 |
| μg/mL | Voriconazole IV |
|---|---|
| Day 1 | 2.97 ± 0.94 |
| Day 7 (up to Day 20) | 4.47 ± 1.44 |
Zero Tmax refers to the highest concentration observed for one participant at predose. The profile of the metabolite is relatively flat, which could result in slight variation in sample collection or assay process.
| hours | Voriconazole IV |
|---|---|
| Day 1 | 4.00 (1.72 to 8.00) |
| Day 7 (up to Day 20) | 4.00 (0.00 to 12.05) |
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Voriconazole Oral |
|---|---|
| AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration | 51.65 ± 27.88 |
| μg/mL | Voriconazole Oral |
|---|---|
| Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration | 5.62 ± 2.54 |
| hours | Voriconazole Oral |
|---|---|
| Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration | 3.97 (0.92 to 8.03) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voriconazole IV | — | 6/40 (15%) | 39/40 (97.5%) |
| Voriconazole Oral | — | 13/34 (38.2%) | 34/34 (100%) |
| Event | Voriconazole IV | Voriconazole Oral |
|---|---|---|
| PyrexiaGeneral disorders | 1/40 | 5/34 |
| Abdominal painGastrointestinal disorders | 0/40 | 1/34 |
| DiarrhoeaGastrointestinal disorders | 0/40 | 1/34 |
| Catheter related complicationGeneral disorders | 0/40 | 1/34 |
| Acute graft versus host disease in skinImmune system disorders | 0/40 | 1/34 |
| Central line infectionInfections and infestations | 0/40 | 1/34 |
| Cytomegalovirus infectionInfections and infestations | 0/40 | 1/34 |
| Enterobacter bacteraemiaInfections and infestations | 0/40 | 1/34 |
| Enterobacter sepsisInfections and infestations | 0/40 | 1/34 |
| Transplant failureInjury, poisoning and procedural complications | 0/40 | 1/34 |
| Event | Voriconazole IV | Voriconazole Oral |
|---|---|---|
| Mucosal inflammationGeneral disorders | 20/40 | 11/34 |
| PyrexiaGeneral disorders | 15/40 | 11/34 |
| HypertensionVascular disorders | 13/40 | 10/34 |
| PruritusSkin and subcutaneous tissue disorders | 12/40 | 10/34 |
| Abdominal painGastrointestinal disorders | 9/40 | 9/34 |
| RashSkin and subcutaneous tissue disorders | 8/40 | 9/34 |
| Alanine aminotransferase increasedInvestigations | 6/40 | 8/34 |
| ConstipationGastrointestinal disorders | 5/40 | 7/34 |
| Aspartate aminotransferase increasedInvestigations | 5/40 | 7/34 |
| AlopeciaSkin and subcutaneous tissue disorders | 6/40 | 7/34 |
| Age, Customized(Participants) | All Participants |
|---|---|
| 2 to <6 years | 24 |
| 6 to <12 years | 16 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 17 |
| Male | 23 |
The record gives a start of Dec 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voriconazole